Ten patients with aplastic anemia (AA) and seven patients with refractory anemia (RA) were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and erythropoietin (rhEpo) in combination. rhG-CSF (5-20 micrograms/kg) and rhEpo (120-720 U/kg) were administered by s.c. injection three times a week for at least six months, and the administration was continued as maintenance therapy for as long as possible when hematological responses were observed. Six (60%) of the ten AA patients and four (58%) of the seven RA patients showed multilineage responses. Of these responders, six patients achieved trilineage recovery. While all of the responders were dependent on red blood cell transfusions and eight of them required platelet transfusions before treatment, they now no longer need transfusions of either red blood cells or platelets. A median treatment duration of 9 (range 1 to 28) months was required to achieve multilineage recovery. The responders showed an ability to maintain the multilineage recovery for 9+ to 47+ months and to tolerate long-term treatment. These results indicate that the long-term treatment with rhG-CSF and rhEpo may benefit a substantial percentage of patients with AA and RA and provide an optional therapy for these patients.

Abstract.A mitochondrial DNA (mtDNA) point mutation at nucleotide pair (np) 3316 has been reported in relation to diabetes.

Background: Recently, robot-assisted thoracic surgery (RATS) is increasingly applied to lung or mediastinal tumor surgery. However, appropriate methods of postoperative analgesia for RATS have not been studied.Methods: Patients who underwent RATS at a single university hospital between January, 2017 and March, 2018 were studied retrospectively. Patients were anesthetized with either general anesthesia alone or combined general and thoracic epidural anesthesia. Accordingly, postoperative analgesia was managed with either intravenous patient-controlled analgesia (PCA) with fentanyl or thoracic epidural analgesia (TEA) with morphine and levobupivacaine. Patients were thus divided into 2 groups (PCA and TEA) according to methods of postoperative analgesia, and analgesic efficacies were compared between the groups with regard to pain scores evaluated on a 11-point numerical rating scale (NRS) at 0, 3, 6, 12, 18, 24, and 48 h postoperatively, rescue analgesic requirements within 24 h, side effects of anesthesia and analgesia, including respiratory depression, hypotension, nausea, pruritus, and urinary retention, time to ambulation after surgery, and hospital stay after surgery.Results: Data from 107 patients (76 in Group PCA and 31 in Group TEA) were analyzed. NRS pain scores at 6, 18, and 48 h were significantly less or tended to be less in Group TEA than in Group PCA (1.8±2.0 vs.

Background: Anaesthetics generally have an immunosuppressive effect, which may be related to prognosis.We conducted to clarify the relationship between peri-operative immunosuppression and anaesthetic agents in patients undergoing lung cancer surgery, resulting in better selection of intraoperative anaesthesia. Methods: Prospective randomized controlled study was performed in single-University hospital. Patients with lung cancer who were scheduled to undergo lung cancer resection between June 2018 and July 2019. Patients were randomly divided to three groups: desflurane (group D), sevoflurane (group S), and propofol (group P) groups. Peripheral blood mononuclear cells were separated from the blood samples. CD4+ and CD8+ T cells, programmed death 1 (PD-1) on CD4+ and CD8+ T cells, and regulatory T cells were measured by flow cytometry. The Wilcoxon signed rank sum test was used to compare pre-and postoperative values for each anaesthesia. Results: Eighty-two patients were enrolled; samples from 64 individuals (20 in group D, 22 in group S, and 22 in group P) were analysed after exclusion. The number of CD8+ T cells was significantly lower after the operation than before the operation in the group P (P<0.05). The proportion of regulatory T cells was significantly increased after surgery, compared with before surgery in the group S (P<0.05). There was no difference in PD-1 on CD4+ and CD8+ T cells after lung surgery among the three groups. Conclusions: Propofol decreased the number of CD8+ T cells, while sevoflurane increased the proportion of regulatory T cells in patients after lung surgery; however, propofol, sevoflurane, and desflurane did not increase the proportion of PD-1 on CD4+ and CD8+ T cells after lung surgery. Sevoflurane and propofol may cause immunosuppression via different mechanisms after lung cancer surgery. Trial Registration: UMIN-CTR: UMIN000031911.

No abstract